Location University of Newcastle, Immunology and Microbiology
Discipline
App. deadline Applications accepted year round/until filled
Funding
  • Please enquire for further details
Eligibility Open to international applicants

Elucidating the roles and therapeutic targeting of macrophages in chronic obstructive pulmonary disease (COPD)/emphysema

Description: COPD is currently the third commonest cause of illness and death in the world and there are essentially no effective treatments. The pathogenesis of COPD is driven by inflammation and macrophages play prominent roles, but protect against infection. They occur in different phenotypes with different functions and properties that can be modified by treatment. Microbiomes are under intense research for their roles in health and disease. Microbiomes and macrophages counter reg

Description: COPD is currently the third commonest cause of illness and death in the world and there are essentially no effective treatments. The pathogenesis of COPD is driven by inflammation and macrophages play prominent roles, but protect against infection. They occur in different phenotypes with different functions and properties that can be modified by treatment. Microbiomes are under intense research for their roles in health and disease. Microbiomes and macrophages counter regulate each other but what this involves ands what impact these changes have are largely unknown. We have shown that reducing macrophages and modifying microbiomes reduce the pathogenesis of experimental COPD. In this project we will 1. characterise the changes in macrophage phenotype in the bone marrow, blood, gut and lungs in experimental COPD, 2. modify microbiomes using antibiotics and 3. faecal transfers of whole faeces or 4. individual bacteria that we implicate in pathogenesis or protection and examine their impact and their potential as treatments. This will be achieved using novel mouse models that we have developed and parallel studies with human cells. This project has the potential to develop new preventions and treatments for COPD. There are two projects here and one will spend half of their time at the University of Manchester.

ulate each other but what this involves ands what impact these changes have are largely unknown. We have shown that reducing macrophages and modifying microbiomes reduce the pathogenesis of experimental COPD. In this project we will 1. characterise the changes in macrophage phenotype in the bone marrow, blood, gut and lungs in experimental COPD, 2. modify microbiomes using antibiotics and 3. faecal transfers of whole faeces or 4. individual bacteria that we implicate in pathogenesis or protection and examine their impact and their potential as treatments. This will be achieved using novel mouse models that we have developed and parallel studies with human cells. This project has the potential to develop new preventions and treatments for COPD. There are two projects here and one will spend half of their time at the University of Manchester.



Please Note: Should this listing mention details of an available scholarship, it is your responsibility to confirm the specifics with the university / institute prior to applyiing. Terms and conditions are in some cases subject to change and are not always reflected immediately within listings.

See our full disclaimer

Further Information / Application Enquiries

Prof Phil Hansbro
+61 2 4042 0187